Patents by Inventor Ian SARVARY

Ian SARVARY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240092794
    Abstract: Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders.
    Type: Application
    Filed: November 6, 2023
    Publication date: March 21, 2024
    Applicant: AMGEN INC.
    Inventors: Shon BOOKER, Matthew Paul BOURBEAU, John R. BUTLER, Sanne Ormholt Schroder GLAD, Brian Alan LANMAN, Patricia LOPEZ, Francesco MANONI, Liping H. PETTUS, Ian SARVARY, Nuria A. TAMAYO, Mikkel VESTERGAARD, Nicholas Anthony WEIRES
  • Publication number: 20230159510
    Abstract: Described herein are compounds of Formula I and pharmaceutically acceptable salt thereof, stereoisomers, tautomers as well as pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders.
    Type: Application
    Filed: February 11, 2021
    Publication date: May 25, 2023
    Applicant: AMGEN INC.
    Inventors: Jennifer Rebecca ALLEN, Albert AMEGADZIE, Diane Jennifer BEYLKIN, Shon BOOKER, Matthew Paul BOURBEAU, John R. BUTLER, Michael J. FROHN, Sanne Ormholt Schroder GLAD, Birgitte Weinreich HUSEMOEN, Matthew R. KALLER, Todd J. KOHN, Brian Alan LANMAN, Kexue LI, Qingyian LIU, Patricia LOPEZ, Vu Van MA, Francesco MANONI, Jose MEDINA, Ana Elena MINATTI, Jorge PEIRO CADAHIA, Liping PETTUS, Alexander J. PICKRELL, Ian SARVARY, Nuria A. TAMAYO, Mikkel VESTERGAARD
  • Publication number: 20220194955
    Abstract: Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders.
    Type: Application
    Filed: December 15, 2021
    Publication date: June 23, 2022
    Applicant: AMGEN INC.
    Inventors: Shon BOOKER, Matthew Paul BOURBEAU, John R. BUTLER, Sanne Ormholt Schroder GLAD, Brian Alan LANMAN, Patricia LOPEZ, Francesco MANONI, Liping H. PETTUS, Ian SARVARY, Nuria A. TAMAYO, Mikkel VESTERGAARD, Nicholas Anthony WEIRES
  • Publication number: 20170342074
    Abstract: Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
    Type: Application
    Filed: July 31, 2015
    Publication date: November 30, 2017
    Inventors: Sanne Schrøder GLAD, Niels Grøn NØRAGER, Ian SARVARY, Alex Haahr GOULIAEV, Lene TEUBER, Luigi Piero STASI
  • Publication number: 20170327503
    Abstract: Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
    Type: Application
    Filed: July 31, 2015
    Publication date: November 16, 2017
    Inventors: Sanne Schrøder GLAD, Kim Birkebæk JENSEN, Niels Grøn NØRAGER, Ian SARVARY, Mikkel VESTERGAARD, Alex Haahr GOULIAEV, Lene TEUBER, Luigi Piero STASI